Menu
Search Close

Investors

Share Information

Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded:

Scancell Holdings securities are listed on AIM, and the latest share price is shown here

The number of securities in issue:

The company has an issued share capital of 465,355,867 ordinary shares of 0.1p each, all of which are called up and fully paid.

Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 3,184,630 ordinary shares to ICHOR at 4.5p per share.

Directors’ Share Options:

The Company has granted the following options to Directors of the Company. 

Option holder

Option price per ordinary share

Number of ordinary shares under option

Last day of exercise period

Sally Adams

10.5p

2,500,000

30 January 2028

John Chiplin

17.0p

3,000,000

18 April 2026

 Lindy Durrant

4.5p

3,850,000

14 July 2020

Lindy Durrant

10.5p

9,000,000

30 January 2028

Richard  Goodfellow

4.5p

2,880,000

14 July 2020

Richard  Goodfellow

33.2p

3,500,000

31 December 2023

Clifford Holloway

10.5p

3,000,000

30 January 2028

 

In addition to the above, the Company has granted options over 1,396,016 shares of the Company to various other persons at exercise prices between 5p and 33.2p.

Percentage of AIM securities not in public hands:

As at 17 June 2019 the percentage of AIM securities not in public hands was: 31.50%

Restrictions on the transfer of securities:

There are no restrictions on the transfer of shares.

Identity and percentage holdings of significant shareholders:

As at 17 June 2019 the identity and percentage holdings of significant shareholders were: 

 

Ordinary shares at 0.1p each

 

 Number

 Percentage

Vulpes Life Science Fund

77,559,311

16.67%

Calculus Capital

49,844,165

10.71%

Scancell Holdings plc directors and related holdings

19,163,147

4.12%

Legal & General Investment Management

16,300,000

3.5%

Webcasts, Interviews and Media Coverage

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

Mon, 01 Jul 2019 11:19:00

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00